Table 2 |
||||
|
Exposures to ≥ 90 days of COX-2 inhibitors, ns-NSAIDs, aspirin and acetaminophen in the year prior to the index date: Crude and adjusted odds ratios. |
||||
|
Exposure to ≥ 90 days |
Cases N of patients (%) |
Controls N of patients (%) |
Crude odds ratios |
Adjusted odds ratios* |
|
|
||||
|
Ns-NSAID/COX-2 inhibitors |
186 (17.1) |
8,681 (19.3) |
0.70 (0.59, 0.84) |
0.75 (0.64, 0.89) |
|
COX-2 inhibitors |
166 (15.2) |
7,412 (16.5) |
0.73 (0.61, 0.88) |
0.81 (0.68, 0.97) |
|
Rofecoxib |
76 (7.0) |
3,597 (8.0) |
0.69 (0.54, 0.89) |
0.80 (0.63, 1.02) |
|
Celecoxib |
93 (8.5) |
3,792 (8.4) |
0.80 (0.64, 1.00) |
0.88 (0.70, 1.10) |
|
Ns-NSAIDs |
24 (2.2) |
1,278 (2.8) |
0.61 (0.40, 0.93) |
0.65 (0.43, 0.99) |
|
Aspirin |
||||
|
average daily dose ≤ 100 mg/day |
78 (7.2) |
2,894 (6.4) |
0.88 (0.69, 1.13) |
0.91 (0.71, 1.16) |
|
average daily dose >100 mg/day# |
211 (19.4) |
8,419 (18.7) |
0.82 (0.69, 0.97) |
0.75 (0.64, 0.89) |
|
Acetaminophen |
74 (6.8) |
2,534 (5.6) |
0.95 (0.74, 1.23) |
0.91 (0.71, 1.16) |
|
Not exposed § |
375 (34.4) |
12,260 (27.3) |
1 (Reference) |
1(Reference) |
|
|
||||
|
* Adjusted for age, mammography in years 2 or 3 prior to index date, breast procedure in the prior 3 years, benign neoplasm of the breast in the prior 3 years, other breast disease in the prior 3 years, estrogen replacement therapy in the prior year, and visit to a gynecologist in the prior year- these variables were risk factors for breast cancer but their inclusion in the model did not alter substantially the effect of exposure to the drugs of interest. #90% of all aspirin prescriptions were for ≤ 325 mg/day §Not exposed refers to the group of patients who were not exposed to ns-NSAIDs, aspirin, COX-2 inhibitors or acetaminophen during the year prior to the index date |
||||
|
Rahme et al. BMC Cancer 2005 5:159 doi:10.1186/1471-2407-5-159 |
||||
